After the Food and Drug Administration (FDA) licensed quadrivalent human papillomavirus vaccine (HPV4) in 2006, reports suggesting a possible association with venous thromboembolism (VTE) emerged from the Vaccine Adverse Event Reporting System and the Vaccine Safety Datalink. Our objective was to determine whether HPV4 increased VTE risk.
a b s t r a c t
After the Food and Drug Administration (FDA) licensed quadrivalent human papillomavirus vaccine (HPV4) in 2006, reports suggesting a possible association with venous thromboembolism (VTE) emerged from the Vaccine Adverse Event Reporting System and the Vaccine Safety Datalink. Our objective was to determine whether HPV4 increased VTE risk.
The subjects were 9−26-year-old female members of five data partners in the FDA's Mini-Sentinel pilot project receiving HPV4 during 2006−2013. The outcome was radiologically confirmed first-ever VTE among potential cases identified by diagnosis codes in administrative data during Days 1−77 after HPV4 vaccination. With a self-controlled risk interval design, we compared counts of first-ever VTE in risk intervals (Days 1−28 and Days 1−7 post-vaccination) and control intervals (Days 36−56 for Dose 1 and Days 36−63 for Doses 2 and 3). Combined hormonal contraceptive use was treated as a potential confounder. The main analyses were: (1) unadjusted for time-varying VTE risk from contraceptive use, (2) unadjusted but restricted to cases without such time-varying risk, and (3) adjusted by incorporating the modeled risk of VTE by week of contraceptive use in the analysis.
Of 279 potential VTE cases identified following 1,423,399 HPV4 doses administered, 225 had obtainable charts, and 53 were confirmed first-ever VTE. All 30 with onsets in risk or control intervals had known risk factors for VTE. VTE risk was not elevated in the first 7 or 28 days following any dose of HPV in any analysis (e.g. relative risk estimate (95% CI) from both unrestricted analyses, for all-doses, 28-day risk interval: 0.7 (0.3−1.4)). Temporal scan statistics found no clustering of VTE onsets after any dose.
Thus, we found no evidence of an increased risk of VTE associated with HPV4 among 9−26-year-old females. A particular strength of this evaluation was its control for both time-invariant and contraceptiverelated time-varying potential confounding.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In June 2006, the Food and Drug Administration (FDA) approved the quadrivalent human papillomavirus vaccine (HPV4; Gardasil; Merck) for the prevention of anogenital cancers, associated precancerous lesions, and genital warts caused by human papillomavirus types 6, 11, 16, and 18 . HPV4 is routinely recommended as a three-dose series (0, 1−2, and 6 months) for those aged 11-12 years but can be administered as young as age 9 years; catch-up vaccination is recommended for females aged 13-26 years and males aged 13-21 years who have not been previously vaccinated [1] . No safety issues were identified in pre-licensure studies involving approximately 21,000 subjects aged 9-26 years [2] .
Post-licensure surveillance identified a possible increased risk of venous thromboembolism (VTE) after HPV4 vaccination. In the first 2.5 years of passive surveillance in the Vaccine Adverse Events Reporting System (VAERS), VTE was reported more frequently following HPV4 than expected using other vaccines for comparison [3] . However, 90% of the reported cases had at least one preexisting known risk factor, and most of the comparison vaccines were childhood vaccines, suggesting that the prevalence of VTE risk factors among adolescents may have explained the disproportionate reporting. To supplement passive surveillance, in the first 3 years after licensure, the Vaccine Safety Datalink (VSD) monitored 600,558 HPV4 doses administered to females aged 9-26 years, checking for increased risks of eight outcomes using sequential analysis methods [4] . No safety signals were detected. However, there was a statistically non-significant relative risk of 1.98 for VTE after HPV4 administration among females aged 9-17 years using a historical comparison group. (If the incidence of adolescent VTE has been increasing [5] , historical controls could have produced bias.) The eight post-HPV4 VTE cases producing this estimate were chartreviewed, and five were confirmed. The VTE diagnosis in four of the five confirmed cases occurred within 7 days after vaccination; the fifth occurred on Day 32. All five cases had at least one known risk factor-contraceptive use, coagulation disorders, smoking, obesity, or prolonged hospitalization. No elevated risk was detected after HPV4 vaccination among females aged 18-26 years.
In December 2010, this information was presented to the FDA Pediatric Advisory Committee as part of a routine safety review [6] . The committee recommended that additional surveillance studies be conducted to further evaluate the risk of VTE, leading to the current study by the Mini-Sentinel/Post-licensure Rapid Immunization Safety Monitoring (PRISM) program [7] . Our objective was to evaluate the risk of VTE following HPV4 vaccination, considering the role of combined hormonal contraceptives (called "contraceptives" below) as a potential confounder or effect modifier.
Three studies finding no association between HPV4 and VTE were published after the launch of our investigation [8] [9] [10] . These are discussed later.
Methods

Study population and data sources
The study population consisted of female HPV4 vaccinees 9-26 years of age from five Mini-Sentinel Data Partners (Aetna, HealthCore, Humana, Optum, and Tennessee Medicaid) during a maximum period of June 2006−June 2013. Inclusion required continuous enrollment, with medical and pharmacy coverage, from 4 months before through at least 70 days after the first dose of HPV4.
Sources of immunization records were claims data from the Data Partners and data from eight participating state/city immunization registries. The source of VTE diagnosis records was insurance claims. Medical records were used to confirm both HPV4 exposure and VTE outcome.
Study design and null hypothesis
A self-controlled risk interval (SCRI) design [11, 12] was used. This design uses only vaccinated cases occurring in a pre-specified risk or comparison interval, and it controls for all potential The control interval for Dose 1 was specified to end earlier to avoid potential bias due to Dose 2 frequently being given during Days 57−63 after Dose 1. The null hypothesis was that the average daily risk of VTE onset during the risk interval was the same as during the control interval.
Exposures
HPV4 vaccination was identified by means of CPT code 90649 and CVX code 62. Both administrative and medical record data were used to establish HPV4 timing and dose number.
Outcomes
We used ICD-9 codes 415.1x (pulmonary embolism, and infarction), 451.x (phlebitis, and thrombophlebitis), and 453.x (other venous embolism, and thrombosis) associated with claims in outpatient, emergency department, and inpatient settings to identify potential cases of VTE. We considered only the first VTE diagnosis found in a patient's claims since enrollment and excluded potential cases with a history of VTE by chart review.
VTE cases were classified using the criteria developed by the Worcester Venous Thromboembolism Study (Table 1 ) [13] . The main analyses were conducted using only definite, i.e. radiologically confirmed, VTE cases. Probable and possible cases were included in secondary analyses. In all analyses, adjudicated symptom onset dates were used, not VTE diagnosis dates based on claims data.
VTE risk factors
We collected data from both claims and medical records on potential cases' VTE risk factors for descriptive purposes and to explore their role as possible effect modifiers of the HPV4−VTE relationship.
Contraceptive use is estimated to increase VTE risk 3-6-fold due to an estrogen-mediated procoagulant state [14] . Some studies have shown a higher risk in the first year of use [15, 16] , especially in the first 3 months. To control for the confounding effect of contraceptive use and also to assess whether such use could be an effect modifier of the association between HPV4 and VTE, the contraceptive use status of all cases was determined using National Drug Codes and Data Partners' "homegrown" codes.
Cases were considered exposed to contraceptives if the dispensing date in the claims data plus total days supplied included the date of the HPV4 dose of interest or any time through the end of the control interval after that dose.
Information on contraceptive usage found in the medical records was used to supplement the claims data in determining contraceptive initiation, duration, and product.
Statistical analyses
The three co-primary analyses used the SCRI design [11, 12] . Analysis #1 included all HPV4 recipients with VTE onset in either the risk or the control interval after an HPV4 dose. It did not adjust for any variation in contraceptive-associated VTE risk that might have existed between risk and control intervals due to recent initiation of contraceptive use.
Analysis #2 was restricted to vaccinees whose baseline risk of VTE was unlikely to have varied between the risk and control intervals due to contraceptive use, i.e. (1) those vaccinees who had no record of contraceptive use as of the last day of the control interval and (2) those vaccinees who had been on contraceptives continuously for at least 9 months (see below) as of the day of the HPV4 dose.
Analysis #3 included the same cases as Analysis #1 but explicitly adjusted for the changing risk of VTE associated with the first 9 months of contraceptive use (see below). In the logistic regression analysis, offset terms were used for vaccinees who initiated contraceptives between 8.99 months prior to the HPV4 dose and the end of the control interval, as inferred from the pharmacy dispensing data and the medical record.
To obtain the offset terms for Analysis #3, the risk of first-ever VTE by duration of contraceptive use was estimated from a risk curve generated from electronic claims data from 9−26-year-old females who had a minimum of 7 months of continuously enrolled time during a maximum period of May 2004−June 2013. Only person-days prior to the first initiation and during the first contraceptive span contributed to the risk curve. Potential VTE cases within 1−28 days following HPV4 were excluded. We used Poisson regression and fit the VTE risk by contraceptive duration (as well as secular month), using progressively higher-order polynomial functions until no statistical significance was found. Age, estrogen dosage, and Data Partner were categorical variables in the model. Terms for plausible interactions were introduced one by one into the modeling to check for effect modification. Goodness-of-fit was determined based on the log-likelihood ratio, p-values of model parameters, Akaike information criterion, and biologic plausibility. Visual inspection of the data together with explorations early in model-building indicated that the risk of VTE during the 9-11.99 months after contraceptive initiation was approximately the same as the risk at ≥ 12 months. Therefore, the VTE risk was considered to plateau starting at 9 months of contraceptive usage.
For Analysis #3, prior to any analysis of the HPV4−VTE association, two sets of offset terms were obtained from the contraceptive-VTE model that was ultimately selected-one for the 28-day risk interval and the other for the 7-day risk interval. First, for each case, we solved the regression equation from the model to determine baseline VTE risk by week during the observation period after HPV4 vaccination. Then, using the predicted values for each week after vaccination for each case, we calculated (for each of the two risk intervals) the area under the contraceptive-VTE risk curve for the risk-interval segment of time as a proportion of the summed areas under the curve for the risk-and control-interval segments of time. We then used that proportion, p (equivalent to the probability of the case being in the risk interval under the null hypothesis of no association between HPV4 and VTE), and calculated ln(p/(1-p)), which served as the offset term for the case and risk interval in question.
Four sets of secondary SCRI analyses were carried out. First, we repeated the analyses, also including the probable and possible VTE cases. Second, we explored the possibility of effect modification by age by repeating Analyses #1 and #3 with age as an interaction term in the model. Third, we checked for possible effect modification by VTE risk factor group by including each of the risk factor groups (as yes/no categorical variables) one by one as interaction terms in the model and repeating Analysis #3. Finally, to address possible concerns that the 28-day risk interval was too short, we repeated Analyses #1-#3 using a Days 1-35 risk interval, first calculating offset terms for this new risk interval.
To check for possible clustering of VTE onsets in the observation period after HPV4 vaccination, we used the temporal scan statistic [17, 18] , a self-controlled design. For Dose 1 and all-doses analyses, we included the definite VTE cases with onset of symptoms 1−56 days after vaccination. For analyses of Doses 2 and 3, we used the definite cases with onsets 1−63 days after vaccination. Using the SaTScan software [19] , we evaluated all potential intervals of increased risk up to 50% of the respective periods, with adjustment for the multiple testing involved.
Chart validation
Charts for both vaccination and VTE visits were sought for potential cases with first-ever VTE diagnoses occurring 1−77 days after a dose of HPV4. (Fourteen days were added to the 63 days in the main observation period in case of delays between symptom onset and date of VTE diagnosis.) A board-certified pediatric hematologist, blinded to the timing of HPV4 vaccination, adjudicated the VTE cases, reviewing medical records, noting or estimating the date of symptom onset, and classifying potential cases as definite, probable, possible, or not-VTE.
The positive predictive value of the VTE identification algorithm was determined by dividing the number of VTE cases classified as definite first-ever VTE by the total number of potential cases identified electronically for which VTE charts were obtained.
Results
The study included 1,423,399 doses of HPV4 vaccine administered, of which 650,475 (46%) appeared to be first doses, 489,737 (34%) second doses, and 283,187 (20%) third doses.
The total number of potential first-ever VTE cases diagnosed within 77 days after a dose of HPV4 vaccine, as ascertained in the electronic claims data, was 279. Charts to confirm/rule out VTE were obtained for 225 of these; 53 were classified as definite, firstever VTE (Fig. 1) , for a positive predictive value of 24%. (Omitting the ambulatory care setting and ICD-9 code 451.x (phlebitis and thrombophlebitis) from the algorithm would have increased this to 65% but at the cost of missing 10 (19% of) confirmed cases [20] .) Of the 53 confirmed cases, 30 had adjudicated onset of symptoms in the risk or control interval after a HPV4 dose and were used in the main SCRI analyses, while five had onset prior to vaccination and 12 had onset after the control interval and were excluded. Six of the 53 definite cases had onset of symptoms in the Days 29−35 period. These were included in sensitivity SCRI analyses as well as in the temporal scan statistical analyses. An additional three probable or possible cases had onset in risk or control intervals and were included in sensitivity SCRI analyses. Among the 30 definite VTE cases included in the main analyses, the most frequent risk factor groups were contraceptive use (23); hypercoagulable states and coagulation defects (16); and transplant, surgery, venous catheterization, and other immobility conditions (12) ( Table 2 ). The number of risk factor groups per patient ranged from 1 to 5 per patient: no patients had 0, 3 patients had 1, 10 had 2, 10 had 3, 5 had 4, and 2 had 5.
Approximately 9,000 potential cases of VTE in roughly 12 million person-years were included in the contraceptive-VTE modeling. Ultimately, and prior to any analysis of the HPV4-VTE association, a model including Data Partner (five levels), contraceptive use (yes/no), estrogen dose (high/low), age group (six levels), (Fig. 2) ), and two interaction terms-age in years × contraceptive status and Data Partner × secular month-was selected as the most appropriate, based on statistical and biological criteria.
None of the three co-primary analyses demonstrated any association between HPV4 and VTE, regardless of dose number or risk interval (Table 3 ). The contraceptive-adjusted results for the unrestricted group (bottom third of the table) were very similar to the unadjusted results for the same group (top third), with a risk estimate for all-doses, with 28-day risk interval, of 0.7 (95% CI: 0.3, 1.4). The second of the three approaches, restricted to patients determined to have no time-varying risk due to contraceptives, had comparatively few cases (middle third), leading to wider confidence intervals.
None of the secondary analyses produced statistically significant results.
The temporal distribution of onsets of definite VTE cases from Day 1 post-vaccination through the last day of the respective control interval is shown in Fig. 3 . None of the temporal scan statistical tests conducted for Doses 1, 2, 3, or all doses combined detected any statistically significant clustering of post-vaccination onset timing (e.g. in all-doses analysis, most likely cluster was Days 48−49, p = 0.26).
Discussion
In this self-controlled study comprising more than 1.4 million doses of HPV4 among more than 650,000 9−26-year-old females in the USA, we found no evidence of an increased risk of VTE. None of the three co-primary analyses or the secondary analyses produced statistically significant results for any of the doses or risk intervals. Likewise, the temporal scan statistical test did not detect any temporal clustering of VTE onsets in the 8−9 weeks after HPV4 vaccination. This result, along with the finding of no increased risk in the sensitivity SCRI analyses using a Days 1-35 risk interval, provide reassurance that we did not miss an increased risk due to misspecifying the risk interval, which could have included time beyond our primary 28-day risk interval.
The strengths of our study are its size, the self-controlled design used to control for time-invariant confounding, the adjustment for potential time-varying confounding from contraceptive use, the Predicted VTE incidence by week in the year after combined hormonal contraceptive initiation. The curve of predicted VTE incidence obtained by modeling VTE risk by duration of contraceptive use is a cubic function to Week 39 (9 months) of contraceptive duration, after which the risk was determined to plateau. The model was used for calculating offset terms for the contraceptive-adjusted Analysis #3. Week 0 represents the first week of contraceptive use (Days 0−6, where Day 0 is the day of the dispensing), and so on. assessment of possible effect modification by age and VTE risk factors, the use of chart review to validate both cases and exposures, and the use of the temporal scan statistic to supplement the main analyses. The shape of the risk curve of VTE by contraceptive duration obtained from modeling and used for the adjustment of the HPV4−VTE analysis (Analysis #3) was consistent with what has been reported in the literature [15] .
Given the control for confounding and other strengths of our study, we consider our null results to be more credible than the association suggested by the VAERS study that found disproportionate reporting of venous thromboembolic events [3] . Considering that VSD saw an elevated (albeit not statistically significant) risk estimate for 9−17 year olds but not for 18−26 year olds [4] , we checked to see if the risk of VTE after HPV4 vaccination varied with age at vaccination and found no evidence of such effect modification by age. Indeed, of the 10 definite cases aged 9−17 years, 4 occurred in the 28-day risk interval and six in the control interval (Table 4) . The lack of association we found is consistent with the results of three more recent studies, which used longer risk intervals. The first, an FDA post-market commitment study, used a SCRI design with two alternative risk intervals, Days 1−14 and Days 1−60, and included approximately 190,000 females in Kaiser Permanente in California who had received at least one dose of HPV4. No increased risk of venous embolism, thromboembolic events, or other clotting disorders was observed [8] . The second was a cohort study comprising more than 696,000 doses of HPV4 administered to females in Denmark and Sweden. No increased risk of VTE was seen using a risk interval of 1−90 days after vaccination (rate ratio 0.86 (95% CI: 0.55−1.36)) [9] . The third used a self-controlled case series design and studied a population of Danish females; 500,345 of these had received HPV4. Using a post-vaccination risk interval of 1−42 days, the investigators found an incidence ratio of 0.77 (95% CI: 0.53−1.11) [10] . One limitation of our study was the possibility of misclassification of contraceptive duration in the contraceptive-adjusted analysis (Analysis #3). However, it seems unlikely that any consistent bias was introduced by such misclassification. Also, charts could not be obtained for about one-fifth of the potential cases identified by the algorithm, reducing our statistical power. Finally, in light of the fact that there were at most 30 definite VTE cases in risk and control intervals, the analyses of effect modification by age and VTE risk factors, which all produced null results, may have had limited power to detect true effect modification of the HPV4−VTE relationship by these factors.
Conclusions
We found no evidence of an increased risk of VTE associated with HPV4 vaccination among 9−26-year-old females in this study comprising more than 1.4 million doses of HPV4 administered. These results, together with those of three recent studies, provide reassurance about the safety of HPV4 with respect to VTE. Particular strengths of our study were the self-controlled design, which controlled for time-invariant confounding, and the adjustment for potential time-varying confounding from contraceptive use.
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